These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 30220082)

  • 21. The role of targeted therapy in the management of patients with AML.
    Perl AE
    Blood Adv; 2017 Nov; 1(24):2281-2294. PubMed ID: 29296877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
    Kim M; Williams S
    Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
    Estey E; Karp JE; Emadi A; Othus M; Gale RP
    Leukemia; 2020 Mar; 34(3):671-681. PubMed ID: 31915366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Midostaurin Gets FDA Nod for AML.
    Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'.
    Bazinet A; Assouline S
    Expert Rev Hematol; 2021 Feb; 14(2):185-197. PubMed ID: 33430671
    [No Abstract]   [Full Text] [Related]  

  • 26. Will new agents impact survival in AML?
    Rowe JM
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101094. PubMed ID: 31779986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise.
    Bohl SR; Bullinger L; Rücker FG
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of Acute Myeloid Leukemia (AML) in Older Patients.
    Abdallah M; Xie Z; Ready A; Manogna D; Mendler JH; Loh KP
    Curr Oncol Rep; 2020 Jul; 22(10):103. PubMed ID: 32725515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New drug approvals in acute myeloid leukemia: an unprecedented paradigm shift.
    Kopmar NE; Estey EH
    Clin Adv Hematol Oncol; 2019 Oct; 17(10):569-575. PubMed ID: 31730583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel therapies for AML: a round-up for clinicians.
    Swaminathan M; Wang ES
    Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1389-1400. PubMed ID: 33412978
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel Agents for Acute Myeloid Leukemia.
    Luppi M; Fabbiano F; Visani G; Martinelli G; Venditti A
    Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30423907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Midostaurin: First Global Approval.
    Kim ES
    Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective.
    Waksal JA; Tallman MS
    Leuk Lymphoma; 2021 Apr; 62(4):779-790. PubMed ID: 33541192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
    Janus SE; Heisler AC; Al Jammal M; Chahine N; Chami T; Hajjari J; Mously H; Badhwar A; Arora S; Al-Juhaishi T; Al-Kindi SG; Hoit BD
    Curr Probl Cardiol; 2022 Nov; 47(11):101345. PubMed ID: 35948197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
    Baron J; Wang ES
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.
    Kantarjian H; Short NJ; DiNardo C; Stein EM; Daver N; Perl AE; Wang ES; Wei A; Tallman M
    Lancet Haematol; 2021 Dec; 8(12):e922-e933. PubMed ID: 34687602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in treatment formulations for acute myeloid leukemia.
    Briot T; Roger E; Thépot S; Lagarce F
    Drug Discov Today; 2018 Dec; 23(12):1936-1949. PubMed ID: 29870791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute myeloid leukemia transformed to a targetable disease.
    Saleh K; Khalifeh-Saleh N; Kourie HR
    Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.